Efficacy of neoadjuvant cisplatin and 5‑flourouracil prior to surgery in FIGO stage IB2/IIA2 cervical cancer

Liu,Shi‑Ping; Yang,Jia‑Xin; Cao,Dong‑Yan; Shen,Keng; Xiang,Yang; Lang,Jing‑He

doi:10.3892/mco.2013.227

March-April 2014 Volume 2 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-April 2014 Volume 2 Issue 2

Full Size Image

Article

Efficacy of neoadjuvant cisplatin and 5‑flourouracil prior to surgery in FIGO stage IB2/IIA2 cervical cancer

Authors:
- Shi‑Ping Liu
- Jia‑Xin Yang
- Dong‑Yan Cao
- Keng Shen
- Yang Xiang
- Jing‑He Lang
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China
Pages: 240-244
|
Published online on: December 18, 2013

https://doi.org/10.3892/mco.2013.227
Expand metrics +

Abstract

Cervical cancer is currently the first or second leading cause of cancer‑related mortality among women in developing countries. This study was conducted in order to determine whether neoadjuvant cisplatin and 5‑flourouracil (NAPF) prior to surgery is superior to primary surgical treatment (PST) as a treatment option for patients with International Federation of Gynaecology and Obstetrics (FIGO) stage IB2̸IIA2 cervical cancer. A retrospective review of 195 patients with early‑stage bulky cervical cancer was performed. The patients were divided into two groups, according to whether they received NAPF prior to surgery. the surgical profiles and complications, risk factors of recurrence and survival were compared between the groups. The response rate to NAPF was found to be 61.2%. There were no differences in operative time and intra‑operative complications between the two groups, whereas the estimated blood loss in the NAPF and PST groups were 620.1±394.9 and 434.8±233.7 ml, respectively (P=0.000). When compared with PST, NAPF remarkably reduced tumor size (22.5 vs. 93.3%, P=0.000). Furthemore, the ratio of deep stromal invasion was significantly lower in responders to NAPF compared with that in non‑responders (46.7 vs. 76.3%, respectively; P=0.004) and in the PST group (46.7 vs. 70.0%, respectively; P=0.004). No reduction of high‑risk factors (HRFs) was observed. The NAPF group, even the responder subgroup, exhibited no significant improvement in progression‑free survival (PFS) and overall survival (OS) compared to the PST group. In conclusion, despite the reduction of intermediate‑risk factors (IRFs), neoadjuvant chemotherapy (NAC) with the NAPF regimen prior to radical surgery (RS) did not improve the prognosis in patients with FIGO stage IB2/IIA2 cervical cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Landoni F, Maneo A, Colombo A, et al: Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 350:535–540. 1997. View Article : Google Scholar : PubMed/NCBI
3	Cai HB, Chen HZ and Yin HH: Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynaecol Res. 32:315–323. 2006. View Article : Google Scholar : PubMed/NCBI
4	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
5	Chen H, Liang C, Zhang L, et al: Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study. Gynecol Oncol. 110:308–315. 2008. View Article : Google Scholar
6	Sardi JE, Giaroli A, Sananes C, et al: Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol. 67:61–69. 1997. View Article : Google Scholar : PubMed/NCBI
7	Eddy GL, Bundy BN, Creasman WT, et al: Treatment of (‘bulky’) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 106:362–369. 2007.
8	Katsumata N, Yoshikawa H, Kobayashi H, et al; Japan Clinical Oncology Group. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 108:1957–1963. 2013. View Article : Google Scholar
9	Napolitano U, Imperato F, Mossa B, et al: The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib–IIIb): a long-term randomized trial. Eur J Gynaecol Oncol. 24:51–59. 2003.
10	Kim HS, Kim JY, Park NH, et al: Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1–IIA cervical cancer. Gynecol Oncol. 119:217–224. 2010.PubMed/NCBI
11	Hu T, Li S, Chen Y, et al: Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1–IIB cervical cancer to establish selection criteria. Eur J Cancer. 48:2353–2360. 2012.
12	Xiong Y, Liang LZ, Cao LP, et al: Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 123:99–104. 2011. View Article : Google Scholar : PubMed/NCBI
13	Lee JY, Kim YH, Kim MJ, et al: Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy. Arch Gynecol Obstet. 284:477–482. 2011. View Article : Google Scholar
14	Rydzewska L, Tierney J, Vale CL, et al: Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 12:CD0074062012.
15	Watari H, Kanuma T, Ohta Y, et al: Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res. 16:345–352. 2010. View Article : Google Scholar
16	Li R, Lu ST, Si JG, et al: Prognostic value of responsiveness of neoadjuvant chemotherapy before surgery for patients with stage IB(2)/IIA(2) cervical cancer. Gynecol Oncol. 128:524–529. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Efficacy of neoadjuvant cisplatin and 5‑flourouracil prior to surgery in FIGO stage IB2/IIA2 cervical cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles